← Back to all signals
RESEARCH PAPER ANALYSIS

The mechanism of external cueing interventions in improving freezing of gait in Parkinson's disease: an fNIRS study.

Using fNIRS in 28 PD-FOG patients and 28 controls, the study shows rhythmic visual or auditory cues (but not their combination) acutely improve gait, increase oxyhemoglobin in PFC and S1, and strengthen functional connectivity among PFC, S1, M1, PMC and temporal/visual areas.

PMID41938069
JournalFrontiers in aging neuroscience
Publication Date2026-01-01
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

Using fNIRS in 28 PD-FOG patients and 28 controls, the study shows rhythmic visual or auditory cues (but not their combination) acutely improve gait, increase oxyhemoglobin in PFC and S1, and strengthen functional connectivity among PFC, S1, M1, PMC and temporal/visual areas.

WHY IT MATTERS

Research significance

Findings clarify cortical hemodynamic and connectivity mechanisms by which external cueing alleviates freezing of gait, supporting non-pharmacological therapies and potential cortical targets/biomarkers for neuromodulation, but provide limited direct molecular targets for drug discovery.

ABSTRACT

Source abstract

INTRODUCTION: External cue interventions can effectively improve gait disturbances in patients with Parkinson's Disease (PD) and Freezing of Gait (FOG). However, the cortical mechanisms underlying cueing modulation of gait have rarely been investigated. OBJECTIVES: We aimed to compare gait performance and cerebral hemodynamic responses in patients with PD and FOG (PD-FOG) under different cueing interventions, and to further elucidate the neural mechanisms underlying the effects of different cues on gait by contrasting these findings with those of Healthy Controls (HCs). METHODS: Twenty-eight PD-FOG patients and 28 HCs were enrolled. Gait parameters were measured during the walking experiment under Rhythmic Visual Cue (RVC) and Rhythmic Auditory Cue (RAC) to compare how these cues affect gait. Functional Near-infrared Spectroscopy (fNIRS) was employed to measure changes in oxyhemoglobin concentration (∆HbO2). Additionally, inter-channel connectivity strength was calculated to evaluate Functional Connectivity (FC) across various Regions of Interest (ROIs). RESULTS: PD-FOG patients exhibit features including decreased gait velocity and stride length during freezing episodes. Both RVC and RAC enhance gait velocity and stride length. Conversely, the combined RVC and RAC (RVC + RAC) intervention did not produce meaningful changes in gait. Compared to HCs, PD-FOG patients show significantly lower ∆HbO2 in the Prefrontal Cortex (PFC) and Primary Somatosensory Cortex (S1). Both RVC and RAC interventions increase ∆HbO2 in the PFC and S1 in PD-FOG patients, whereas the RVC + RAC intervention decreases ∆HbO2 in the Premotor Cortex (PMC). Furthermore, compared with HCs, PD-FOG patients show increased FC between the S1-PFC and Primary Motor Cortex (M1)-PFC. The RVC intervention enhances FC within the PFC and between the PMC and the Visual Association Cortex (V2). The RAC intervention strengthens FC within the PFC and the PFC-Middle Temporal Gyrus (MTG). The RVC + RAC intervention increases FC within the PFC-MTG and PFC-PMC, partially compensating for functional deficits associated with cortical hypoactivation by enhancing connectivity among these ROIs. CONCLUSION: Single visual or auditory cues can improve FOG symptoms. RVC and RAC alleviate FOG by modulating cortical activation and enhancing FC between key ROIs. The heightened connectivity among these ROIs may represent the underlying neural pathway that mediates the cue-induced alleviation of FOG.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic